• 1
    American Heart Association. Heart Disease and Stroke Statistics Update. Dallas, TX: American Heart Association; 2005.
  • 2
    American College of Cardiology. ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult summary article. A Report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol. 2005;46 (6):11161143.
  • 3
    Bhalla V, Willis S, Maisel A. B-type natriuretic peptide: the level and the drug-partners in the diagnosis of congestive heart failure. Congestive Heart Fail. 2004;10 (1, suppl 1):327.
  • 4
    Maisel A. B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail. 2001;7 (2):183193.
  • 5
    Masson S, Latini R, Anand I, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val HeFT) data. Clin Chem. 2006;52 (8):15281538.
  • 6
    Brenden C, Hollander J, Guss D, et al. Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am Heart J. 2006;151 (5):10061111.
  • 7
    Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure guideline. J Card Fail. 2006;12 (1):1038.
  • 8
    Heidenreich P, Gubens M, Fonarow G, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43 (6):10191026.
  • 9
    MacMahon K, Lip G. Psychological factors in heart failure: a review of literature. Arch Intern Med. 2002;162 (3):509516.
  • 10
    Maisel A, Krisihnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347 (3):161168.
  • 11
    Troughton R, Frampton C, Yandle T, et al. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355 (9210):11261130.
  • 12
    Cheng V, Kazanegra R, Garcia A, et al. Rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37 (2):386391.
  • 13
    Mueller C, Scholer A, Laule-Kilian K, et al. Use of b-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350 (7):647654.
  • 14
    Prahash A, Lynch T. B-type natriuretic peptide: a diagnostic prognostic, and therapeutic tool in heart failure. Am J Crit Care. 2004;13 (1):4653.
  • 15
    Wieczorek S, Wu A, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144 (5):834839.
  • 16
    Mueller T, Laule-Klian K, Schindler L, et al. Cost-effectiveness of b-type natriuretic peptide testing in patients with acute dypsnea. Arch Intern Med. 2006;166 (10):10811088.
  • 17
    Krüger S, Graf J, Kunz D, et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002;40a (4):718722.
  • 18
    Rickhamm PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. BMJ. 1964;2 (5402):177.
  • 19
    Biosite Incorporated, San Diego, CA. Triage BNP immunoassay test product insert. New dimensions in diagnosis. 2004;121.
  • 20
    Rector T. A conceptual model of quality of life in relation to heart failure. J Card Fail. 2005;11 (3):173176.
  • 21
    Rector T, Cohn J. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124 (4):10171025.
  • 22
    SAS Institute Incorporated. The SAS System (Version 8.2, Windows Workstation) [Computer Software]. Cary, NC: SAS institute Incorporation; 2001.
  • 23
    Sagnella G. Measurement and significance of circulating natriuretic peptide in cardiovascular disease. Clin Sci. 1998;95 (5):519529.
  • 24
    Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6 (3):261268.
  • 25
    Mair J, Friedl W, Thomas S, et al. Natriuretic peptide in assessment of left ventricular dysfunction. Scan J Clin Lab Invest. 1999;230:132142.
  • 26
    Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005;11 (7):498503.
  • 27
    Krittayaphong R, Boonyasirinant T, Saiviroonporn P, et al. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail. 2008;14 (8):687694.
  • 28
    Anker S. Mid-regional pro-adrenomedullin (MRproADM) versus BNP & NTproBNP as prognosticator in heart failure patients: results from the BACH multinational study. Presented at the American Heart Association 2008 Scientific Sessions, November 11, 2008, New Orleans, LA.